Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Oraxol in Cancer Patients
NCT04180384Phase 2Completed
- Sponsor
- Athenex
- Start
- Sep 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of paclitaxel + encequidar in solid tumor (2 arms), sponsored by Athenex. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Sep 2015; status: completed.
02
Drugs
paclitaxel + encequidar
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04180384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180384.